CLS-B.ST
Clinical Laserthermia Systems AB (publ) [CLS-B.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CLS-B.ST Stock Summary
Top 10 Correlated Stocks
CLS-B.ST
In the News
CLS-B.ST Financial details
Company Rating
Neutral
Market Cap
156.28M
Income
-82.21M
Revenue
8.27M
Book val./share
0.03
Cash/share
0.01
Dividend
-
Dividend %
-
Employees
14
Optionable
No
Shortable
Yes
Earnings
17 May 2024
P/E
-3.03
Forward P/E
-
PEG
1.23
P/S
24.7
P/B
3.46
P/C
9.4
P/FCF
-4.45
Quick Ratio
3.06
Current Ratio
4.29
Debt / Equity
0.01
LT Debt / Equity
-
-
-
EPS (TTM)
-0.21
EPS next Y
-
EPS next Q
-
EPS this Y
-57.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-17.81%
Revenue last 5Y
42.14%
Revenue Q/Q
125.28%
EPS Q/Q
-49.6%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-101%
ROE
-444%
ROC
-0.89%
Gross Margin
18%
Oper. Margin
-684%
Profit Margin
-902%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.072-0.721306
52W High
-
52W Low
-
RSI
51
Rel Volume
0.56
Avg Volume
11.02M
Volume
6.18M
Perf Week
16.77%
Perf Month
2.17%
Perf Quarter
-25.4%
Perf Half Y
-27.41%
-
-
-
-
Beta
0.476
-
-
Volatility
0.01%, 0.01%
Prev Close
8.05%
Price
0.094
Change
6.33%
CLS-B.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | |
| Net income per share | -0.32 | -0.35 | -0.32 | -0.28 | -0.12 | |
| Operating cash flow per share | -0.28 | -0.32 | -0.3 | -0.28 | -0.1 | |
| Free cash flow per share | -0.28 | -0.32 | -0.3 | -0.28 | -0.11 | |
| Cash per share | 0.04 | 0.07 | 0.14 | 0.04 | 0.02 | |
| Book value per share | 0.05 | 0.08 | 0.1 | 0.04 | 0.07 | |
| Tangible book value per share | -0.12 | -0.04 | 0.01 | -0.04 | 0.06 | |
| Share holders equity per share | 0.05 | 0.08 | 0.1 | 0.04 | 0.07 | |
| Interest debt per share | 0.02 | 0.02 | 0.03 | 0.16 | 0.01 | |
| Market cap | 846.22M | 776.57M | 896.47M | 210.25M | 92.7M | |
| Enterprise value | 845.13M | 776.65M | 895.03M | 230.48M | 77.83M | |
| P/E ratio | -18.95 | -12.69 | -12.8 | -2.97 | -1.16 | |
| Price to sales ratio | 593.42 | 583.01 | 399.32 | 33.54 | 11.21 | |
| POCF ratio | -21.63 | -14.02 | -13.55 | -2.97 | -1.4 | |
| PFCF ratio | -21.63 | -13.93 | -13.43 | -2.95 | -1.29 | |
| P/B Ratio | 120.94 | 55.76 | 41.13 | 22.81 | 2.03 | |
| PTB ratio | 120.94 | 55.76 | 41.13 | 22.81 | 2.03 | |
| EV to sales | 592.66 | 583.07 | 398.68 | 36.77 | 9.41 | |
| Enterprise value over EBITDA | -21.44 | -15.05 | -16.29 | -3.99 | -1.23 | |
| EV to operating cash flow | -21.6 | -14.02 | -13.53 | -3.26 | -1.17 | |
| EV to free cash flow | -21.6 | -13.93 | -13.41 | -3.23 | -1.08 | |
| Earnings yield | -0.05 | -0.08 | -0.08 | -0.34 | -0.86 | |
| Free cash flow yield | -0.05 | -0.07 | -0.07 | -0.34 | -0.78 | |
| Debt to equity | 0.15 | 0.05 | 0.01 | 3.33 | 0.01 | |
| Debt to assets | 0.03 | 0.02 | 0 | 0.62 | 0 | |
| Net debt to EBITDA | 0.03 | 0 | 0.03 | -0.35 | 0.24 | |
| Current ratio | 0.4 | 0.7 | 0.93 | 0.58 | 1.94 | |
| Interest coverage | -33.18 | -15.84 | -9.47 | -6.15 | -6.74 | |
| Income quality | 0.9 | 0.96 | 1.04 | 1 | 0.83 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 26.54 | 30.14 | 18.99 | 0 | 0 | |
| Research and developement to revenue | 1.67 | 1.78 | 0.94 | 0.34 | 0 | |
| Intangibles to total assets | 0.61 | 0.48 | 0.29 | 0.36 | 0 | |
| Capex to operating cash flow | 0 | 0.01 | 0.01 | 0.01 | 0.08 | |
| Capex to revenue | 0 | -0.26 | -0.25 | -0.09 | -0.67 | |
| Capex to depreciation | 0 | -0.11 | -0.81 | -0.23 | -2.06 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.59 | 0.8 | 0.85 | 0.47 | 0.43 | |
| ROIC | -5.4 | -3.75 | -3 | -1.68 | -1.41 | |
| Return on tangible assets | -2.99 | -2.64 | -1.49 | -2.22 | -1.38 | |
| Graham Net | -0.15 | -0.07 | -0.03 | -0.08 | 0.01 | |
| Working capital | -18.51M | -9.13M | -3.03M | -17.38M | 13.17M | |
| Tangible asset value | -16.72M | -7.32M | 1.59M | -9.8M | 43.53M | |
| Net current asset value | -19.12M | -9.57M | -3.13M | -17.38M | 12.95M | |
| Invested capital | 0.15 | 0.05 | 0.01 | 3.33 | 0.01 | |
| Average receivables | 4.26M | 5.62M | 6.69M | 9.64M | 8.94M | |
| Average payables | 6.22M | 5.95M | 4.39M | 5.12M | 7.55M | |
| Average inventory | 2.57M | 2.28M | 3.45M | 2.83M | 3.81M | |
| Days sales outstanding | 1.27K | 1.72K | 1.16K | 709.27 | 251.44 | |
| Days payables outstanding | 2.69K | 3.57K | 268.02 | 239.12 | 45.15 | |
| Days of inventory on hand | 655.19 | 2.2K | 258.14 | 60.28 | 30.12 | |
| Receivables turnover | 0.29 | 0.21 | 0.32 | 0.51 | 1.45 | |
| Payables turnover | 0.14 | 0.1 | 1.36 | 1.53 | 8.08 | |
| Inventory turnover | 0.56 | 0.17 | 1.41 | 6.05 | 12.12 | |
| ROE | -6.38 | -4.39 | -3.21 | -7.67 | -1.74 | |
| Capex per share | 0 | 0 | 0 | 0 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.01 | 0 | 0.01 | 0 | 0 | |
| Net income per share | -0.04 | -0.05 | -0.1 | -0.04 | -0.02 | |
| Operating cash flow per share | -0.04 | -0.05 | -0.09 | -0.05 | -0.01 | |
| Free cash flow per share | -0.04 | -0.06 | -0.09 | -0.06 | -0.01 | |
| Cash per share | 0.03 | 0.01 | 0.04 | 0.07 | 0.01 | |
| Book value per share | 0.02 | 0.01 | -0.07 | 0.14 | 0.03 | |
| Tangible book value per share | -0.02 | -0.03 | -0.19 | 0.1 | 0.03 | |
| Share holders equity per share | 0.02 | 0.01 | -0.07 | 0.14 | 0.03 | |
| Interest debt per share | 0.08 | 0.01 | 0.02 | 0 | 0 | |
| Market cap | 327.67M | 579.56M | 22.8M | 72.8M | 184.33M | |
| Enterprise value | 347.9M | 574.32M | 17.17M | 42.8M | 169.46M | |
| P/E ratio | -5.06 | -6.11 | -0.35 | -1.08 | -1.83 | |
| Price to sales ratio | 76.29 | 987.33 | 18.21 | 36.8 | 41.37 | |
| POCF ratio | -20.22 | -24.45 | -1.5 | -3.04 | -14.48 | |
| PFCF ratio | -19.55 | -22.1 | -1.48 | -2.82 | -12.37 | |
| P/B Ratio | 35.55 | 126.96 | -1.9 | 1.14 | 4.03 | |
| PTB ratio | 35.55 | 126.96 | -1.9 | 1.14 | 4.03 | |
| EV to sales | 81 | 978.4 | 13.72 | 21.64 | 38.03 | |
| Enterprise value over EBITDA | -5.47K | -39.62 | -1.05 | -2.87 | -8.73 | |
| EV to operating cash flow | -21.47 | -24.23 | -1.13 | -1.79 | -13.31 | |
| EV to free cash flow | -20.75 | -21.9 | -1.12 | -1.66 | -11.37 | |
| Earnings yield | -0.05 | -0.04 | -0.72 | -0.23 | -0.14 | |
| Free cash flow yield | -0.05 | -0.05 | -0.67 | -0.35 | -0.08 | |
| Debt to equity | 3.33 | 0 | 0 | 0 | 0.01 | |
| Debt to assets | 0.62 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -317.95 | 0.36 | 0.34 | 2.01 | 0.77 | |
| Current ratio | 0.58 | 0.36 | 0.27 | 4.29 | 1.94 | |
| Interest coverage | -5.81 | -3.88 | -6.64 | -15.74 | -341.47 | |
| Income quality | 1 | 1 | 0.92 | 1.43 | 0.5 | |
| Dividend Yield | 0.03 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.65 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.5 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.36 | 0.45 | 0.4 | 0.25 | 0 | |
| Capex to operating cash flow | 0.03 | 0.11 | 0.01 | 0.08 | 0.17 | |
| Capex to revenue | -0.13 | -4.28 | -0.17 | -0.92 | -0.49 | |
| Capex to depreciation | -1.28 | -3.9 | -0.32 | -2.71 | -2.94 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.14 | 0.11 | 0.41 | 0.35 | 0.12 | |
| ROIC | -0.34 | -3.66 | 1.42 | -0.24 | -0.43 | |
| Return on tangible assets | -0.51 | -1.07 | -0.62 | -0.31 | -0.44 | |
| Graham Net | -0.05 | -0.06 | -0.29 | 0.06 | 0.01 | |
| Working capital | -17.38M | -23.83M | -42.28M | 32.45M | 13.17M | |
| Tangible asset value | -9.8M | -15.21M | -31.4M | 43.66M | 43.53M | |
| Net current asset value | -17.38M | -23.83M | -42.28M | 32.22M | 12.95M | |
| Invested capital | 3.33 | 0 | 0 | 0 | 0.01 | |
| Average receivables | 12.87M | 8.72M | 5.28M | 5.6M | 5.8M | |
| Average payables | 5.32M | 4.66M | 3.94M | 5.03M | 7.37M | |
| Average inventory | 2.47M | 1.45M | 2.22M | 3.09M | 4.63M | |
| Days sales outstanding | 255.23 | 805.86 | 380.77 | 268.13 | 115.11 | |
| Days payables outstanding | 123.54 | 480.33 | 346.36 | 1.01K | 33.54 | |
| Days of inventory on hand | 31.15 | 199.98 | 233.71 | 572.25 | 22.37 | |
| Receivables turnover | 0.35 | 0.11 | 0.24 | 0.34 | 0.78 | |
| Payables turnover | 0.73 | 0.19 | 0.26 | 0.09 | 2.68 | |
| Inventory turnover | 2.89 | 0.45 | 0.39 | 0.16 | 4.02 | |
| ROE | -1.76 | -5.19 | 1.37 | -0.26 | -0.55 | |
| Capex per share | 0 | -0.01 | 0 | 0 | 0 |
CLS-B.ST Frequently Asked Questions
What is Clinical Laserthermia Systems AB (publ) stock symbol ?
Clinical Laserthermia Systems AB (publ) is a SE stock and trading under the symbol CLS-B.ST
What is Clinical Laserthermia Systems AB (publ) stock quote today ?
Clinical Laserthermia Systems AB (publ) stock price is $0.094 today.
Is Clinical Laserthermia Systems AB (publ) stock public?
Yes, Clinical Laserthermia Systems AB (publ) is a publicly traded company.
Company Profile
- Volume Average 11.02M
- Market Capitalization 156.28M
- Employee 14
- CEO Mr. Dan Johansson Mogren
- Headquarters Lund,SE
- IPO Date 2009-04-16
-
Website
https://www.clinicallaser.se 
Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
